ABSTRACT Doxorubicin (DXR) was covalently conjugated to a monoclonal antibody (mAb), 9.2.27 (IgG2a), which recognizes a chondroitin sulfate proteoglycan expressed preferentially on the surface of human melanoma cells. Immuno-conjugates with a molar ratio of DXR to mAb ranging from 2:1 to 10:1 were obtained by coupling the drug via an acid-sensitive linker, cis-aconitic anhydride. The immunoreactivity of mAb 9.2.27 was well retained after conjugation. DXR-mAb 9.2.27 conjugates were found to be 2 orders of magnitude more potent in killing tumor cells in vitro (ICSo = 0.1 ,LM) than free drug targeted to drug receptors(s). Most significantly, DXR-imAb 9.2.27 immunoconugates specifically suppressed the growth of established tumors in vivo and prolonged the life-span of tumor-bearing nude mice. This suppression of melanoma growth achieved by the immunoconjugate was both tumor and antibody specific. A biodistribution study indicated that DXR-mAb 9.2.27 conjugates delivered at least 4 times more DXR (3.7% total injected dose per g of tumor) as compared to free DXR alone (0.8% total injected dose per g of tumor) in tumor-bearing nude mice 48 hr postinjection. The tumor-suppressive effects of DXR-mAb 9.2.27 conjugates are even more remarkable since free DXR did not suppress tumor growth in vivo and also because this drug per se is known to be quite ineffective for the treatment of human melanoma.
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The potential usefulness of monoclonal antibodies (mAbs) to deliver drugs, radionuclides, or toxins to tumor sites in vivo has been under active investigation (1) (2) (3) . mAbs directed against well-characterized tumor-associated antigens have made it possible to critically evaluate their suitabilities as carriers for cytotoxic molecules or radionuclides. The use of such immunoconjugates for accurate delivery of lethal agents to human tumor targets promises to create a generation of treatment modalities that may reduce side effects, facilitate more selective tumor targeting, result in improved therapeutic indices and decreased lethal doses, and possibly even decrease the incidence of multiple drug resistance.
Specifically, mAb 9.2.27, recognizing a melanomaassociated chondroitin sulfate proteoglycan expressed preferentially on the cell surface of human melanoma cells (4) , was previously shown to only partially suppress the human melanoma xenograft in nude mice when conjugated with a diphtheria toxin A chain (5) . In this report, we conjugated a chemotherapeutic drug, doxorubicin (DXR), to mAb 9.2.27 via an acid-sensitive linker, cis-aconitic anhydride. This linker between the macromolecule and the drug was reported to preserve both antibody and DXR activities (6, 7) . It is postulated that such conjugates remain stable at the intravascular pH of 7.4, but once endocytosed by the target cell, the drug is cleaved in the more acidic environment of endosomes and lysosomes and intercalated with nuclear DNA (8) (9) (10) . The results of our study showed that such immunoconjugates not only retained good immunoreactivity and pharmacological activity in vitro but also effectively suppressed established human melanoma xenografts in an athymic (nu/nu) mouse model.
MATERIALS AND METHODS
Cells. UCLA-SO-M21 melanoma cells (M21) were maintained in vitro as described (4, 5) . Neuroepithelioma cells (NMB-7) kindly provided by S. K. Liao (McMaster University, Canada) and adenocarcinoma of the lung cells (UCLA-SO-P3; UCLA-P3) were maintained in culture.
Antibodies. mAb 9.2.27 (IgG2a) recognizes a proteoglycan preferentially expressed on human melanoma cells (4). mAb 11.4.1 (IgG2a), directed against a mouse H-2Kk antigen, was obtained from American Type Culture Collection. mAbs were purified by protein A-Sepharose chromatography (11) .
Conjugation of DXR to mAbs. Conjugation of DXR to mAbs was achieved by an acid-sensitive linker, cis-aconitic anhydride, with modifications (6, 7) . Briefly, 12 mg of cis-aconitic anhydride (Sigma) was dissolved in 3 ml of a 50% aqueous solution of p-dioxane at 250C and added dropwise to an ice-cold solution of DXR (12 mg in 6 ml of distilled water) and keeping the pH at 9.0 by the addition of 0.5 M NaOH. After 15 min, the pH was adjusted to 7.0 and continued for another 1 hr. Six milligrams of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (Sigma) was then added to the solution for 30 min, followed by 6 mg of mAb (10 mg/ml in P,/NaCl, pH 7.0). The reaction proceeded at pH 7.0 for 3 hr at 250C. The immunoconjugates were purified with Sephadex G-25 Fine (Pharmacia) and dialyzed against P1/NaCl at 40C. The molar ratio of mAb to DXR was determined by assessing protein concentration with a protein dye-binding assay (Bio-Rad) (12) ELISA. The retention of mAb activity after conjugation was determined with an ELISA as described (13 (Fig. 1) is antigen specific, both an irrelevant mAb, 11.4.1 (IgG2a) directed against a mouse H-2Kk antigen, and a normal mouse IgG were conjugated to DXR using the same protocol as for mAb 9.2.27 (IgG2a). Results showed that at equivalent doses of DXR, only DXR-mAb 9.2.27 conjugates inhibited proliferation of M21 cells (Fig. 2) . In contrast, DXR conjugated to either irrelevant mAb 11.4.1 or normal mouse IgG failed to achieve any significant inhibition of tumor cell growth. Immunology: Yang and Reisfeld tMann.Whitney U test; P < 0.01.
was localized in the nuclei of M21 cells after 30 min incubation at 37rC (daa not shown). The nuclei-associated fluorescence in these cells was resistant to RNase but sensitive to DNase treatment, indicating that DXR was bound to nuclear DNA. Under identical conditions (30 min at 3rC), DXR-mAb 9.2.27 conjugates were predominantly observed in the cytoplasm. However, after a 2-hr incubation at 37TC, the majority of fluorescence was found in the nucleus (Fig. 3 A and B) . This time lag required for the DXR-mAb 9.2.27 to enter the nucleus prompted an examination of the possible involvement of lysosomal degradation of DXR-mAb conjugates during this process. As expected, when the pH ofthe lysosomal compartment of M21 cells was increased by treatment with 25 Am chloroquine, the majority of fluorescence was localized in a perinuclear region of these cells after a 2-hr incubation with DXR-mAb 9.2.27 at 37TC (Fig. 3 C and D) . In a control experiment, chloroquine treatment (25 ,uM) alone did not affect either the transport or DNA-binding ability of free DXR (data not shown).
DXR-mAb 9.2.27 Conjugates S lly Suppress Tumor Growth in Vivo. The efficacy and specificity of DXR-mAb 9.2.27 conjugates to suppress tumor growth in vivo are shown in Fig. 4 and Table 1 . Results indicated that only mice treated with DXR-mAb 9.2.27 conjugate demonstrated significant suppression of tumor growth in a tumor-and antibody-specific fashion-i.e., DXR-mAb 9.2.27 conjugates had no effect on the growth of the irrelevant UCLA-P3 tumors (Fig. 4B) , which lack the 9.2.27 epitopes, and the irrelevant DXR-mAb conjugate, DXR-inAb 11.4.1, was ineffective against the melanoma tumors. In contrast, 8/12 M21 melanoma xenografts in the nude mice treated with the DXR-mAb 9.2.27 conjugates remained very small for the first 31 days after tumor inoculation and gradually increased in volume at a much slower rate than those in the other experimental groups (Fig. 4A) . However, 4 of 12 mice in this same experimental group actually showed tumor regression and remained tumor free for the duration of the experiment. DXR treatment alone failed to significantly suppress the tumor growth of both M21 melanoma and UCLA-P3 lung adenocarcinoma in tumor-bearing mice ( Fig. 4 ; P > 0.1). In addition, a mixture of mAb 9.2.27 and DXR also showed similar negative effects as DXR alone (Fig. 4A) . The median survival time of animals treated with mAb 9.2.27 alone was 55 days; however, the life-span of animals receiving DXRmAb 9.2.27 treatment was prolonged by 81% (P < 0.01) with 4 of 12 mice still surviving on day 120 (Table 1) .
Biodistribution of Free DXR and DXR-mAb 9.2.27 Conjugates. The most striking finding was the preferential deposition of DXR in tumor delivered by DXR-mAb 9.2.27 as compared to that of freely administered drug ( (Fig.  4A ). Mice treated with the DXR-mAb 9.2.27 conjugate also showed an 81% increase in life-span (Table 1 ). This improvement was considerably greater than that of 27% achieved with animals treated with DXR alone (Table 1) . These data clearly demonstrate that growth of an established tumor can be markedly suppressed by the DXR-mAb 9.2.27 conjugates. Results of biodistribution studies further indicate that mAb 9.2.27 is able to deliver at least 4-fold more drug (3.7% of injected dose per g of tumor) than that of DXR in free drug form (0.8% of injected dose per g of tumor) to the tumor target (Table 2) . Moreover, only free DXR, but not DXRmAb 9.2.27 conjugates, was accumulated in the bone. Therefore, conjugated DXR showed overall far better localization indices than those obtained with free DXR. These data are consistent with the specific tumor suppression and increased life-span observed in the group of nude mice treated with DXR-mAb 9.2.27 ( Fig. 4 and Table 1 ). Thus, DXR-mAb 9.2.27 conjugates effectively increase selective toxicity of free DXR. A similar result was obtained in a syngeneic mouse tumor model using methotrexate conjugated with an anti-EL4 lymphoma antibody, which localized well in EL4 lymphoma in tumor-bearing mice 24 hr after i.p. injection (21) .
The toxicity study in nude mice indicated that 400 ,jg of free DXR (two 200-,g injections at a 3-day interval) will kill 100%1o of animals within 6 days. In addition, the dose is cumulative in nude mice-i.e., four doses of 100 ,ug of free DXR will kill the mice within 14 days. Therefore, the dose used in this study, a total equivalent dose of 75 ,ug of DXR per mouse, can be significantly increased without toxicity. These data also indicate that our present drug delivery is still quite suboptimal and that even better results may be achieved under optimal conditions. To gain some understanding of the mechanism(s) by which the DXR-mAb 9.2.27 conjugates suppress tumor growth, the initial binding, internalization, processing, and degradation of DXR-mAb conjugates was investigated in M21 melanoma cells. The fact that excess native mAb 9.2.27 can reverse the growth inhibition exerted by DXR-mAb 9.2.27 conjugates (data not shown) suggests that the immunoconjugate enters the tumor target cell via an antigen-antibody complex rather than by diffusion as has been proposed for free drug by other investigators (22) . This hypothesis was further supported by a binding study in which [14C]DXR-mAb 9.2.27 conjugates bound to M21 but not to control NMB-7 cells that do not express the 9.2.27 epitope (unpublished data). Taken together, these data suggest that DXR-mAb conjugates are effective only after they are internalized. Furthermore, the results from experiments conducted with chloroquine ( Fig. 
